Parliamentary questions can be asked by any MSP to the Scottish Government or the Scottish Parliamentary Corporate Body. The questions provide a means for MSPs to get factual and statistical information.
Urgent Questions aren't included in the Question and Answers search. There is a SPICe fact sheet listing Urgent and emergency questions.
Displaying 630 questions Show Answers
To ask the Scottish Government whether the High Risk Medicines Framework is currently in use in NHS Scotland.
To ask the Scottish Government whether it will provide an update on the progress of the roll-out of Hospital Electronic Prescribing and Medicines Administration (HEPMA) in each NHS board, and when it expects that each NHS board will have HEPMA capability.
To ask the Scottish Government what policies and protocols are currently in place in NHS Scotland to ensure that people whose medicine is time-critical, such as those with Parkinson’s disease, receive their medication on time, every time, including when they are in hospital.
To ask the Scottish Government what policies and procedures are in place to support medicines reconciliation for all hospital inpatients upon (a) admission to, (b) transfer within and (c) discharge from hospital.
To ask the Scottish Government how the medicines reconciliation process for all inpatients is monitored within each NHS hospital.
To ask the Scottish Government whether it will provide an update on how it is supporting the arts sector.
To ask the Scottish Government what steps it is taking to increase recruitment for staff in older people's medicine (a) across Scotland and (b) in NHS Ayrshire and Arran.
To ask the Scottish Government what the objectives are of the ScotRail timetable consultation for the upcoming May 2023 timetable, and for what reasons each objective has been chosen.
To ask the Scottish Government when the ScotRail timetable consultation for the upcoming May 2023 timetable concluded, and when the findings will be published.
To ask the Scottish Government whether it will provide a list of all of its Special Advisers, broken down by portfolio area.